(CL) Colgate-Palmolive - Ratings and Ratios
Toothpaste, Soap, Shampoo, Detergent, Pet Food
CL EPS (Earnings per Share)
CL Revenue
Description: CL Colgate-Palmolive
Colgate-Palmolive (NYSE: CL) is a U.S.–based consumer-goods company that operates two primary segments: Oral, Personal & Home Care and Pet Nutrition. The first segment sells a broad array of daily-use products-including toothpaste, soaps, shampoos, deodorants, and household cleaners-under well-known brands such as Colgate, Palmolive, Tom’s of Maine, and Irish Spring, reaching traditional brick-and-mortar retailers, e-commerce platforms, wholesalers, dentists, and skin-health professionals.
The Pet Nutrition segment is focused on Hill’s Science Diet (everyday nutrition) and Hill’s Prescription Diet (therapeutic formulas) and distributes primarily through pet-supply chains, veterinary clinics, and online retailers. Both segments benefit from the company’s global footprint, with sales spanning the United States and more than 200 international markets.
Key recent metrics (FY 2023) show net sales of roughly $17.4 billion, an operating margin of about 15 %, and a dividend yield near 2.5 %. The oral-care market is a $50 billion defensive niche, while pet-nutrition is growing at an estimated 5 % CAGR, driven by increasing pet-ownership rates and premiumization trends.
Sector drivers that materially affect CL’s performance include (1) consumer-price-inflation pressure on discretionary spend, (2) currency-exchange volatility given the company’s exposure to emerging-market earnings, and (3) the ongoing shift toward e-commerce, which has accelerated the adoption of direct-to-consumer channels for both oral-care and pet-nutrition products.
For a data-rich, forward-looking analysis of how these dynamics translate into valuation risk and upside, you may find ValueRay’s platform worth a deeper look.
CL Stock Overview
| Market Cap in USD | 63,946m |
| Sub-Industry | Household Products |
| IPO / Inception | 1977-01-03 |
CL Stock Ratings
| Growth Rating | -2.08% |
| Fundamental | 76.0% |
| Dividend Rating | 57.1% |
| Return 12m vs S&P 500 | -29.2% |
| Analyst Rating | 3.77 of 5 |
CL Dividends
| Dividend Yield 12m | 2.58% |
| Yield on Cost 5y | 2.94% |
| Annual Growth 5y | 3.14% |
| Payout Consistency | 99.6% |
| Payout Ratio | 56.4% |
CL Growth Ratios
| Growth Correlation 3m | -86.7% |
| Growth Correlation 12m | -65.2% |
| Growth Correlation 5y | 65.3% |
| CAGR 5y | 5.36% |
| CAGR/Max DD 3y (Calmar Ratio) | 0.19 |
| CAGR/Mean DD 3y (Pain Ratio) | 0.63 |
| Sharpe Ratio 12m | -0.86 |
| Alpha | -26.61 |
| Beta | 0.335 |
| Volatility | 17.71% |
| Current Volume | 6773.7k |
| Average Volume 20d | 5949.7k |
| Stop Loss | 77.4 (-3.1%) |
| Signal | 0.39 |
Piotroski VR‑10 (Strict, 0-10) 6.5
| Net Income (2.91b TTM) > 0 and > 6% of Revenue (6% = 1.20b TTM) |
| FCFTA 0.19 (>2.0%) and ΔFCFTA -1.09pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue -3.90% (prev 1.48%; Δ -5.38pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.22 (>3.0%) and CFO 3.92b > Net Income 2.91b (YES >=105%, WARN >=100%) |
| Net Debt (7.54b) to EBITDA (4.80b) ratio: 1.57 <= 3.0 (WARN <= 3.5) |
| Current Ratio 0.89 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (816.5m) change vs 12m ago -0.88% (target <= -2.0% for YES) |
| Gross Margin 60.57% (prev 59.69%; Δ 0.88pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 117.8% (prev 121.3%; Δ -3.48pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 16.21 (EBITDA TTM 4.80b / Interest Expense TTM 259.0m) >= 6 (WARN >= 3) |
Altman Z'' 7.91
| (A) -0.04 = (Total Current Assets 6.00b - Total Current Liabilities 6.78b) / Total Assets 17.47b |
| (B) 1.53 = Retained Earnings (Balance) 26.73b / Total Assets 17.47b |
| warn (B) unusual magnitude: 1.53 — check mapping/units |
| (C) 0.25 = EBIT TTM 4.20b / Avg Total Assets 16.98b |
| (D) 1.48 = Book Value of Equity 24.28b / Total Liabilities 16.42b |
| Total Rating: 7.91 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 76.03
| 1. Piotroski 6.50pt = 1.50 |
| 2. FCF Yield 4.71% = 2.36 |
| 3. FCF Margin 16.85% = 4.21 |
| 4. Debt/Equity 12.48 = -2.50 |
| 5. Debt/Ebitda 1.57 = 0.82 |
| 6. ROIC - WACC (= 30.26)% = 12.50 |
| 7. RoE 679.7% = 2.50 |
| 8. Rev. Trend 81.62% = 6.12 |
| 9. EPS Trend -29.77% = -1.49 |
What is the price of CL shares?
Over the past week, the price has changed by +3.56%, over one month by +1.30%, over three months by -9.36% and over the past year by -17.94%.
Is Colgate-Palmolive a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of CL is around 70.52 USD . This means that CL is currently overvalued and has a potential downside of -11.7%.
Is CL a buy, sell or hold?
- Strong Buy: 7
- Buy: 6
- Hold: 7
- Sell: 1
- Strong Sell: 1
What are the forecasts/targets for the CL price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 90.7 | 13.6% |
| Analysts Target Price | 90.7 | 13.6% |
| ValueRay Target Price | 77.2 | -3.3% |
Last update: 2025-10-21 02:29
CL Fundamental Data Overview
P/E Trailing = 22.2247
P/E Forward = 19.802
P/S = 3.1976
P/B = 90.1592
P/EG = 1.596
Beta = 0.335
Revenue TTM = 20.00b USD
EBIT TTM = 4.20b USD
EBITDA TTM = 4.80b USD
Long Term Debt = 7.14b USD (from longTermDebt, last quarter)
Short Term Debt = 1.61b USD (from shortTermDebt, last quarter)
Debt = 8.76b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 7.54b USD (from netDebt column, last quarter)
Enterprise Value = 71.49b USD (63.95b + Debt 8.76b - CCE 1.22b)
Interest Coverage Ratio = 16.21 (Ebit TTM 4.20b / Interest Expense TTM 259.0m)
FCF Yield = 4.71% (FCF TTM 3.37b / Enterprise Value 71.49b)
FCF Margin = 16.85% (FCF TTM 3.37b / Revenue TTM 20.00b)
Net Margin = 14.55% (Net Income TTM 2.91b / Revenue TTM 20.00b)
Gross Margin = 60.57% ((Revenue TTM 20.00b - Cost of Revenue TTM 7.88b) / Revenue TTM)
Gross Margin QoQ = 60.06% (prev 60.82%)
Tobins Q-Ratio = 4.09 (Enterprise Value 71.49b / Total Assets 17.47b)
Interest Expense / Debt = 0.81% (Interest Expense 71.0m / Debt 8.76b)
Taxrate = 23.24% (234.0m / 1.01b)
NOPAT = 3.22b (EBIT 4.20b * (1 - 23.24%))
Current Ratio = 0.89 (Total Current Assets 6.00b / Total Current Liabilities 6.78b)
Debt / Equity = 12.48 (Debt 8.76b / totalStockholderEquity, last quarter 702.0m)
Debt / EBITDA = 1.57 (Net Debt 7.54b / EBITDA 4.80b)
Debt / FCF = 2.24 (Net Debt 7.54b / FCF TTM 3.37b)
Total Stockholder Equity = 428.0m (last 4 quarters mean from totalStockholderEquity)
RoA = 16.65% (Net Income 2.91b / Total Assets 17.47b)
RoE = 679.7% (Net Income TTM 2.91b / Total Stockholder Equity 428.0m)
RoCE = 55.45% (EBIT 4.20b / Capital Employed (Equity 428.0m + L.T.Debt 7.14b))
RoIC = 36.71% (NOPAT 3.22b / Invested Capital 8.78b)
WACC = 6.45% (E(63.95b)/V(72.70b) * Re(7.25%) + D(8.76b)/V(72.70b) * Rd(0.81%) * (1-Tc(0.23)))
Discount Rate = 7.25% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: -100.0 | Cagr: -0.52%
[DCF Debug] Terminal Value 79.70% ; FCFE base≈3.37b ; Y1≈3.73b ; Y5≈4.85b
Fair Price DCF = 104.2 (DCF Value 84.22b / Shares Outstanding 808.2m; 5y FCF grow 12.34% → 3.0% )
EPS Correlation: -29.77 | EPS CAGR: -56.56% | SUE: -4.0 | # QB: 0
Revenue Correlation: 81.62 | Revenue CAGR: 5.11% | SUE: 0.42 | # QB: 0
Additional Sources for CL Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle